Literature DB >> 29899093

The Influenza B Virus Hemagglutinin Head Domain Is Less Tolerant to Transposon Mutagenesis than That of the Influenza A Virus.

Benjamin O Fulton1, Weina Sun1, Nicholas S Heaton2, Peter Palese3,4.   

Abstract

Influenza A and B viruses can continuously evade humoral immune responses by developing mutations in the globular head of the hemagglutinin (HA) that prevent antibody binding. However, the influenza B virus HA over time displays less antigenic variation despite being functionally and structurally similar to the influenza A virus HA. To determine if the influenza B virus HA is under constraints that limit its antigenic variation, we performed a transposon screen to compare the mutational tolerance of the currently circulating influenza A virus HAs (H1 and H3 subtypes) and influenza B virus HAs (B/Victoria87 and B/Yamagata88 antigenic lineages). A library of insertional mutants for each HA was generated and deep sequenced after passaging to determine where insertions were tolerated in replicating viruses. The head domains of both viruses tolerated transposon mutagenesis, but the influenza A virus head was more tolerant to insertions than the influenza B virus head domain. Furthermore, all five of the known antigenic sites of the influenza A virus HA were tolerant of 15 nucleotide insertions, while insertions were detected in only two of the four antigenic sites in the influenza B virus head domain. Our analysis demonstrated that the influenza B virus HA is inherently less tolerant of transposon-mediated insertions than the influenza A virus HA. The reduced insertional tolerance of the influenza B virus HA may reveal genetic restrictions resulting in a lower capacity for antigenic evolution.IMPORTANCE Influenza viruses cause seasonal epidemics and result in significant human morbidity and mortality. Influenza viruses persist in the human population through generating mutations in the hemagglutinin head domain that prevent antibody recognition. Despite the similar selective pressures on influenza A and B viruses, influenza A virus displays a higher rate and breadth of antigenic variability than influenza B virus. A transposon mutagenesis screen was used to examine if the reduced antigenic variability of influenza B virus was due to inherent differences in mutational tolerance. This study demonstrates that the influenza A virus head domain and the individual antigenic sites targeted by humoral responses are more tolerant to insertions than those of influenza B virus. This finding sheds light on the genetic factors controlling the antigenic evolution of influenza viruses.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  influenza virus; insertional mutagenesis; transposons; viral evolution

Mesh:

Substances:

Year:  2018        PMID: 29899093      PMCID: PMC6069205          DOI: 10.1128/JVI.00754-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity.

Authors:  Peter S Lee; Reiko Yoshida; Damian C Ekiert; Naoki Sakai; Yasuhiko Suzuki; Ayato Takada; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-01       Impact factor: 11.205

2.  The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype).

Authors:  A J Caton; G G Brownlee; J W Yewdell; W Gerhard
Journal:  Cell       Date:  1982-12       Impact factor: 41.582

3.  Homology model of the structure of influenza B virus HA1.

Authors:  Chang-Shung Tung; Joshua L Goodman; Henry Lu; Catherine A Macken
Journal:  J Gen Virol       Date:  2004-11       Impact factor: 3.891

4.  Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol.

Authors:  Nicole M Bouvier; Anice C Lowen; Peter Palese
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

5.  A one-plasmid system to generate influenza virus in cultured chicken cells for potential use in influenza vaccine.

Authors:  Xiangmin Zhang; Wei Kong; Shamaila Ashraf; Roy Curtiss
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

6.  The influenza virus hemagglutinin cytoplasmic tail is not essential for virus assembly or infectivity.

Authors:  H Jin; G P Leser; R A Lamb
Journal:  EMBO J       Date:  1994-11-15       Impact factor: 11.598

7.  Genome-wide evolutionary dynamics of influenza B viruses on a global scale.

Authors:  Pinky Langat; Jayna Raghwani; Gytis Dudas; Thomas A Bowden; Stephanie Edwards; Astrid Gall; Trevor Bedford; Andrew Rambaut; Rodney S Daniels; Colin A Russell; Oliver G Pybus; John McCauley; Paul Kellam; Simon J Watson
Journal:  PLoS Pathog       Date:  2017-12-28       Impact factor: 6.823

8.  Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes.

Authors:  Teddy John Wohlbold; Kira A Podolsky; Veronika Chromikova; Ericka Kirkpatrick; Veronica Falconieri; Philip Meade; Fatima Amanat; Jessica Tan; Benjamin R tenOever; Gene S Tan; Sriram Subramaniam; Peter Palese; Florian Krammer
Journal:  Nat Microbiol       Date:  2017-08-21       Impact factor: 17.745

9.  The inherent mutational tolerance and antigenic evolvability of influenza hemagglutinin.

Authors:  Bargavi Thyagarajan; Jesse D Bloom
Journal:  Elife       Date:  2014-07-08       Impact factor: 8.140

Review 10.  Acid-induced membrane fusion by the hemagglutinin protein and its role in influenza virus biology.

Authors:  Charles J Russell
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

View more
  14 in total

1.  A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice.

Authors:  Alec W Freyn; Jamile Ramos da Silva; Victoria C Rosado; Carly M Bliss; Matthew Pine; Barbara L Mui; Ying K Tam; Thomas D Madden; Luís Carlos de Souza Ferreira; Drew Weissman; Florian Krammer; Lynda Coughlan; Peter Palese; Norbert Pardi; Raffael Nachbagauer
Journal:  Mol Ther       Date:  2020-04-19       Impact factor: 11.454

2.  Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.

Authors:  Weina Sun; Ericka Kirkpatrick; Megan Ermler; Raffael Nachbagauer; Felix Broecker; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

3.  Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice.

Authors:  Angela Choi; Badiaa Bouzya; Klaus-Daniel Cortés Franco; Daniel Stadlbauer; Arvind Rajabhathor; Ronan N Rouxel; Roland Mainil; Marie Van der Wielen; Peter Palese; Adolfo García-Sastre; Bruce L Innis; Florian Krammer; Michael Schotsaert; Corey P Mallett; Raffael Nachbagauer
Journal:  Immunohorizons       Date:  2019-04-01

4.  Characterization of Novel Cross-Reactive Influenza B Virus Hemagglutinin Head Specific Antibodies That Lack Hemagglutination Inhibition Activity.

Authors:  Ericka Kirkpatrick; Carole Henry; Meagan McMahon; Kaijun Jiang; Shirin Strohmeier; Harm van Bakel; Patrick C Wilson; Florian Krammer
Journal:  J Virol       Date:  2020-11-09       Impact factor: 5.103

5.  Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.

Authors:  Felix Broecker; Allen Zheng; Nungruthai Suntronwong; Weina Sun; Mark J Bailey; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

6.  Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice.

Authors:  Felix Broecker; Sean T H Liu; Weina Sun; Florian Krammer; Viviana Simon; Peter Palese
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

7.  Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans.

Authors:  Weina Sun; Davina S Kang; Allen Zheng; Sean T H Liu; Felix Broecker; Viviana Simon; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

8.  Enhancing Neuraminidase Immunogenicity of Influenza A Viruses by Rewiring RNA Packaging Signals.

Authors:  Allen Zheng; Weina Sun; Xiaoli Xiong; Alec W Freyn; Julia Peukes; Shirin Strohmeier; Raffael Nachbagauer; John A G Briggs; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

9.  A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains.

Authors:  Felix Broecker; Sean T H Liu; Nungruthai Suntronwong; Weina Sun; Mark J Bailey; Raffael Nachbagauer; Florian Krammer; Peter Palese
Journal:  NPJ Vaccines       Date:  2019-07-19       Impact factor: 7.344

10.  An Inactivated Influenza Virus Vaccine Approach to Targeting the Conserved Hemagglutinin Stalk and M2e Domains.

Authors:  Weina Sun; Allen Zheng; Robert Miller; Florian Krammer; Peter Palese
Journal:  Vaccines (Basel)       Date:  2019-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.